Literature DB >> 26324269

Greater ciprofloxacin tolerance as a possible selectable phenotype underlying the pandemic spread of the H30 subclone of Escherichia coli sequence type 131.

James R Johnson1, Stephen B Porter2, Paul Thuras3, Timothy J Johnson4, Lance B Price5, Veronika Tchesnokova6, Evgeni V Sokurenko6.   

Abstract

Minimum bactericidal concentrations (MBCs) for ciprofloxacin were significantly higher among 41 members of the H30 subclone within Escherichia coli sequence type 131 than among 48 other fluoroquinolone-resistant E. coli isolates. This MBC difference, which was not explained by ciprofloxacin MICs, gyrA, parC, and parE mutations, the presence of aac(6')-Ib-cr, or organic solvent tolerance (a surrogate for efflux pump activity), conceivably could have promoted the pandemic emergence of the H30 sequence type 131 subclone.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26324269      PMCID： PMC4604381          DOI： 10.1128/AAC.01687-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Phenotypic tolerance: antibiotic enrichment of noninherited resistance in bacterial populations.

Authors:  C Wiuff; R M Zappala; R R Regoes; K N Garner; F Baquero; B R Levin
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase.

Authors:  Ari Robicsek; Jacob Strahilevitz; George A Jacoby; Mark Macielag; Darren Abbanat; Chi Hye Park; Karen Bush; David C Hooper
Journal:  Nat Med       Date:  2005-12-20       Impact factor: 53.440

3.  Joint tolerance to beta-lactam and fluoroquinolone antibiotics in Escherichia coli results from overexpression of hipA.

Authors:  T J Falla; I Chopra
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

4.  Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States.

Authors:  James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Mariana Castanheira
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

5.  Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen.

Authors:  Deborah A Williamson; Sally A Roberts; David L Paterson; Hanna Sidjabat; Anna Silvey; Jonathan Masters; Michael Rice; Joshua T Freeman
Journal:  Clin Infect Dis       Date:  2012-03-14       Impact factor: 9.079

6.  Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones.

Authors:  J S Wolfson; D C Hooper; D J Shih; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

7.  Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates.

Authors:  Antonio Sorlozano; Jose Gutierrez; Antonio Jimenez; Juan de Dios Luna; José Luis Martínez
Journal:  J Clin Microbiol       Date:  2007-06-13       Impact factor: 5.948

8.  Escherichia coli sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients.

Authors:  James R Johnson; Brian Johnston; Connie Clabots; Michael A Kuskowski; Swaroop Pendyala; Chitrita Debroy; Bogdan Nowicki; James Rice
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

9.  Transmission of an extended-spectrum-beta-lactamase-producing Escherichia coli (sequence type ST131) strain between a father and daughter resulting in septic shock and Emphysematous pyelonephritis.

Authors:  Peter T Ender; Deepakraj Gajanana; Brian Johnston; Connie Clabots; Frank J Tamarkin; James R Johnson
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

10.  Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009.

Authors:  James R Johnson; Marie-Hélène Nicolas-Chanoine; Chitrita DebRoy; Mariana Castanheira; Ari Robicsek; Glen Hansen; Scott Weissman; Carl Urban; Joanne Platell; Darren Trott; George Zhanel; Connie Clabots; Brian D Johnston; Michael A Kuskowski
Journal:  Emerg Infect Dis       Date:  2012-04       Impact factor: 6.883
View more
  8 in total

1.  Pandemic fluoroquinolone resistant Escherichia coli clone ST1193 emerged via simultaneous homologous recombinations in 11 gene loci.

Authors:  Veronika Tchesnokova; Matthew Radey; Sujay Chattopadhyay; Lydia Larson; Jamie Lee Weaver; Dagmara Kisiela; Evgeni V Sokurenko
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-01       Impact factor: 11.205

2.  Limited Multidrug Resistance Efflux Pump Overexpression among Multidrug-Resistant Escherichia coli Strains of ST131.

Authors:  Johannes Camp; Sabine Schuster; Martina Vavra; Tobias Schweigger; John W A Rossen; Sandra Reuter; Winfried V Kern
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

3.  Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.

Authors:  Brian D Johnston; Paul Thuras; Stephen B Porter; Melissa Anacker; Brittany VonBank; Paula Snippes Vagnone; Medora Witwer; Mariana Castanheira; James R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

4.  The Pandemic H30 Subclone of Escherichia coli Sequence Type 131 Is Associated With Persistent Infections and Adverse Outcomes Independent From Its Multidrug Resistance and Associations With Compromised Hosts.

Authors:  James R Johnson; Paul Thuras; Brian D Johnston; Scott J Weissman; Ajit P Limaye; Kim Riddell; Delia Scholes; Veronika Tchesnokova; Evgeni Sokurenko
Journal:  Clin Infect Dis       Date:  2016-03-29       Impact factor: 9.079

5.  Bacterial clonal diagnostics as a tool for evidence-based empiric antibiotic selection.

Authors:  Veronika Tchesnokova; Hovhannes Avagyan; Elena Rechkina; Diana Chan; Mariya Muradova; Helen Ghirmai Haile; Matthew Radey; Scott Weissman; Kim Riddell; Delia Scholes; James R Johnson; Evgeni V Sokurenko
Journal:  PLoS One       Date:  2017-03-28       Impact factor: 3.240

6.  High Risk Clone: A Proposal of Criteria Adapted to the One Health Context with Application to Enterotoxigenic Escherichia coli in the Pig Population.

Authors:  Maud de Lagarde; Ghyslaine Vanier; Julie Arsenault; John Morris Morris Fairbrother
Journal:  Antibiotics (Basel)       Date:  2021-02-28

7.  Global Evolution of Pathogenic Bacteria With Extensive Use of Fluoroquinolone Agents.

Authors:  Miklos Fuzi; Jesus Rodriguez Baño; Akos Toth
Journal:  Front Microbiol       Date:  2020-02-25       Impact factor: 5.640

8.  In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-Resistant Escherichia coli from Southeastern China.

Authors:  Na Huang; Tao Chen; Liqiong Chen; Ying Zhang; Yishuai Lin; Xiangkuo Zheng; Tieli Zhou; Lijiang Chen
Journal:  Infect Drug Resist       Date:  2021-06-30       Impact factor: 4.003
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.